Lupkynis Prescribing & Dosing Schedule

Dosage & Administration Drug label Prior authorization Financial assistance Patient education People also ask

Lupkynis(voclosporin)

Lupkynis 7.9 MG Oral Capsule

Dosage & Administration

Administration:

* LUPKYNIS must be swallowed whole on an empty stomach. ( 2.1)
* Administer consistently as close to a 12-hour schedule as possible, and with at least 8 hours between doses. ( 2.1)
* If a dose is missed, instruct the patient to take it as soon as possible within 4 hours after missing the dose. Beyond the 4-hour time frame, instruct the patient to wait until the usual scheduled time to take the next regular dose. Instruct the patient not to double the next dose. ( 2.1)
* Instruct patients to avoid eating grapefruit or drinking grapefruit juice while taking LUPKYNIS. ( 2.1, 7.1)

Dosage Recommendations:

* Before initiating LUPKYNIS, establish an accurate baseline estimated glomerular filtration rate (eGFR) and check blood pressure (BP).
* Use of LUPKYNIS is not recommended in patients with a baseline eGFR ≤45 mL/min/1.73 m2 unless the benefit exceeds the risk; these patients may be at increased risk for acute and/or chronic nephrotoxicity. ( 2.2, 5.3)
* Do not initiate LUPKYNIS in patients with baseline BP >165/105 mmHg or with hypertensive emergency. ( 2.2, 5.4)

* Recommended starting dose: 23.7 mg orally, twice a day. ( 2.3)
* Use LUPKYNIS in combination with mycophenolate mofetil (MMF) and corticosteroids. ( 2.3)
* Modify the LUPKYNIS dose based on eGFR ( 2.3, 5.3):
* Assess eGFR every two weeks for the first month, every four weeks through the first year, and quarterly thereafter.
* If eGFR <60 mL/min/1.73 m2 and reduced from baseline by >20% and <30%, reduce the dose by 7.9 mg twice a day. Re-assess eGFR within two weeks; if eGFR is still reduced from baseline by >20%, reduce the dose again by 7.9 mg twice a day.
* If eGFR <60 mL/min/1.73 m2 and reduced from baseline by ≥30%, discontinue LUPKYNIS. Re-assess eGFR within two weeks; consider re-initiating LUPKYNIS at a lower dose (7.9 mg twice a day) only if eGFR has returned to ≥80% of baseline.
* For patients that had a decrease in dose due to eGFR, consider increasing the dose by 7.9 mg twice a day for each eGFR measurement that is ≥80% of baseline; do not exceed the starting dose.

* Monitor blood pressure every two weeks for the first month after initiating LUPKYNIS, and as clinically indicated thereafter. For patients with BP >165/105 mmHg or with hypertensive emergency, discontinue LUPKYNIS and initiate antihypertensive therapy. ( 2.3, 5.4)
* If the patient has not experienced therapeutic benefit by 24 weeks, consider discontinuation of LUPKYNIS. ( 2.3)

Dosage Adjustments:

* Patients with severe renal impairment: the recommended dose is 15.8 mg twice daily. ( 2.4, 8.6)
* Patients with mild and moderate hepatic impairment: the recommended dose is 15.8 mg twice daily. ( 2.4, 8.7)

drug label

Lupkynis Prescribing Information

Contact Medical Science Liaison

Report Adverse Event

prior authorization

Lupkynis Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Jun 26, 2024Arizona - Uniform Prior Authorization Form

Verified: Jun 26, 2024Colorado - Uniform Prior Authorization Form

Verified: Jun 26, 2024Hawaii - Uniform Prior Authorization Form

Verified: Jul 26, 2024Illinois - Uniform Prior Authorization Form

Verified: Jun 26, 2024Indiana - Uniform Prior Authorization Form

Verified: Jun 26, 2024Louisiana - Uniform Prior Authorization Form

Verified: Jun 26, 2024Minnesota - Uniform Prior Authorization Form

Verified: Jun 26, 2024New Hampshire - Uniform Prior Authorization Form

Verified: Jun 26, 2024New Mexico - Uniform Prior Authorization Form

Verified: Jun 26, 2024Oregon - Uniform Prior Authorization Form

Verified: Jun 26, 2024Texas - Uniform Prior Authorization Form

Verified: Jul 07, 2024Washington - Uniform Prior Authorization Form

Verified: Jul 07, 2024Wisconsin - Uniform Prior Authorization Form

Complete Letter of Medical Necessity

Coverage Appeals Checklist

Benefits investigation

Lupkynis Start Form

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

financial assistance

Lupkynis Financial Assistance Options

Copay savings program

Lupkynis Start Form

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

Lupkynis Start Form

Bridge Program

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

patient education

Lupkynis Patient Education

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link

Patient toolkit

About Lupkynis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

View How to Take Lupkynis & Side Effects

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient Resources

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Doctor Discussion Guide

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Lupkynis FAQs

How is the dosage of Lupkynis?Lupkynis is available in 1 dosages, including 7.9 mg Cap

What does Lupkynis treat?Lupkynis treats Lupus Nephritis

What is Lupkynis made of?Lupkynis contains voclosporin which is a Calcineurin Inhibitor Immunosuppressant

How Is Lupkynis Administered?Lupkynis is administered as a Oral Pill

What Are The Lupkynis Mechanism Of Action?Lupkynis mechanism of action is Calcineurin Inhibitors, Organic Anion Transporting Polypeptide 1B1 Inhibitors, Organic Anion Transporting Polypeptide 1B3 Inhibitors or P-Glycoprotein Inhibitors

FAQ Data Source

Dosage & Administration

Dosage & Administration

drug label

Lupkynis Prescribing Information

prior authorization

Lupkynis Prior Authorization Resources

Most recent state uniform prior authorization forms

Benefits investigation

Reimbursement help (FRM)

financial assistance

Lupkynis Financial Assistance Options

Copay savings program

Bridge program

patient education

Lupkynis Patient Education

Patient toolkit

people also ask

Lupkynis FAQs